🧪 Psilocybin is about to be FDA approved. The lab version, that is

Hey Micronaut,

To close out Mental Health Awareness Month, I want to share something genuinely good. Something a lot of us in this community have believed for a long time is finally being taken seriously at the highest level.

A few weeks ago I wrote to you about the news out of Washington, the push to fast track psychedelic research after decades of the door being firmly shut. Since then it has moved further and faster than most people expected.

Psilocybin, the compound in the truffles you already know, is now near the front of the line. For the first time ever, regulators have put it on a fast track normally reserved for the most urgent medicines. If it clears review, possibly within months, it would become the first psilocybin medicine ever approved by the FDA. The federal stamp that lets a treatment be prescribed right across the country.

That is a real milestone, and worth pausing on. Fifty years of stigma quietly giving way to evidence. We are glad to see it.

There is one detail in the story that confuses people, though, and it is worth understanding. The version heading for approval is not a mushroom. It is synthetic, made in a lab. That is not a scandal and it is not nature being snubbed. It is simply how the system is built. Here is what it actually means.

Same molecule, different origin

First, the reassuring part. Psilocybin is psilocybin. The molecule is the same whether it grows inside a truffle or gets built on a lab bench. This is not new chemistry, either. The Swiss chemist Albert Hofmann first isolated pure psilocybin from a mushroom back in 1959. We have known how to copy nature here for more than sixty years.

So what is the difference? A synthetic formulation is the single molecule on its own. Isolated, purified, measured out to an exact milligram. Clean and consistent, every batch identical.

A natural truffle is the molecule plus its company. Alongside psilocybin sit small amounts of related compounds (psilocin, baeocystin, aeruginascin and others). There is a hypothesis, borrowed from cannabis research, that this supporting cast may subtly shape the overall experience. It is called the entourage effect, and it is worth being honest about its status. It is a hypothesis, not a settled fact. Interesting, plausible, and still being studied.

That is the whole distinction. Not a different drug. The same active molecule, either standing alone or in the context nature grew it in.

Why the lab version goes first

Once you see how drug approval works, the synthetic-first order makes complete sense.

Regulators are built to evaluate a single, well defined molecule. They want known purity, an exact dose, and a product that is identical from one batch to the next, so a trial can be repeated and trusted. A lab made molecule fits that mould perfectly. A mushroom, which varies with its strain and growing conditions and carries several compounds at once, is much harder to standardise into a clean clinical trial.

Then there is the money, and this connects to something I wrote about earlier this month. A late stage trial costs hundreds of millions. A company will only spend that when there is a patent at the end of it, something it can own and recoup the cost on. You can patent a novel synthetic formulation. You cannot patent a mushroom that grows in the ground.

Put those together and the result is not a conspiracy. It is gravity. The molecule that is easiest to standardise and possible to own is the one that flows through the approval machine first. Synthetic going first is the path of least resistance, not a verdict on what works best.

Will the natural version ever follow?

Here is the part most coverage misses. Natural psilocybin is not waiting in line behind the synthetic version. It is already on a different road.

Whole mushroom psilocybin is already used legally, in supervised and state regulated settings. Oregon opened its service centres in 2023 and has guided thousands of people since. Colorado followed, licensing its first healing centres in 2025, and New Mexico legalised a programme of its own the same year. None of these went through the federal drug approval route at all. They were created directly through public votes and state law. Same molecule, natural source, a completely separate path to access.

Could whole mushroom material ever earn a formal FDA drug approval too? That is a longer shot, for exactly the standardisation and patent reasons above. But the science on those supporting compounds is young and active, and curiosity about the full plant is growing, not shrinking.

So the honest answer to “synthetic or natural?” is that it was never really a race. It is two roads. One built for pharmacies and clinics, tidy and standardised and supervised. One that stays closer to the plant itself. Both are moving forward at the same time.

Where we stand, plainly

We are not here to tell you what to take, and we are not making any claim about treating or curing anything. That is genuinely not our place, and it never will be.

What we will say is simpler. We are glad this molecule is finally being studied seriously, by anyone, on any road. That is good for all of us. And our own preference, which is a preference and not a medical claim, has always been for the natural source, kept close to the way it grows. The truffle is exactly that.

A good note to end the month on. The compound that was dismissed for half a century is being taken seriously again. Whether it reaches people through a clinic or stays closer to the earth, the direction is the same. Forward.

Flow strong,

Gino, founder of Microdose Pro

P.S. Pure psilocybin is not a modern invention. Albert Hofmann pulled it out of a mushroom in 1959. The lab has known how to copy this particular bit of nature for more than sixty years. Nature, as usual, simply got there first. 🍄